Tradename | Company | Number | Date | Products |
---|---|---|---|---|
AMVUTTRA | Alnylam Pharmaceuticals | N-215515 RX | 2022-06-13 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
amvuttra | New Drug Application | 2023-01-27 |
Expiration | Code | ||
---|---|---|---|
VUTRISIRAN SODIUM, AMVUTTRA, ALNYLAM PHARMS INC | |||
2029-06-13 | ODE-212 | ||
2027-06-13 | NCE |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Vutrisiran Sodium, Amvuttra, Alnylam Pharms Inc | |||
10208307 | 2036-07-28 | DS, DP | U-3396 |
10683501 | 2036-07-28 | DS, DP | U-3396 |
11286486 | 2036-07-28 | DS, DP | U-3396 |
10612024 | 2035-08-14 | DS, DP | U-3396 |
11401517 | 2035-08-14 | DS, DP | U-3396 |
9399775 | 2032-11-16 | DS, DP | U-3396 |
10570391 | 2032-11-16 | DS, DP | U-3396 |
8106022 | 2029-12-12 | DS, DP | U-3396 |
8828956 | 2028-12-04 | DS, DP | U-3396 |
9370581 | 2028-12-04 | DS, DP | U-3396 |
10806791 | 2028-12-04 | DP | |
10131907 | 2028-08-24 | DS, DP | U-3396 |
Code | Description |
---|---|
J0225 | Injection, vutrisiran, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | — | 3 | — | 1 | 5 |
Familial amyloid neuropathies | D028227 | — | E85.1 | — | — | 3 | — | — | 3 |
Familial amyloidosis | D028226 | — | — | — | — | 1 | — | 1 | 2 |
Takotsubo cardiomyopathy | D054549 | EFO_1002000 | I51.81 | — | — | 2 | — | — | 2 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Polyneuropathies | D011115 | EFO_0009562 | A69.22 | — | — | — | — | 1 | 1 |
Drug common name | Vutrisiran |
INN | vutrisiran |
Description | Vutrisiran, sold under the brand name Amvuttra, is a medication used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is a double stranded small interfering RNA (siRNA) (also called RNA interference, or RNAi therapeutic) that interferes with the expression of the transthyretin (TTR) gene. Transthyretin is a serum protein made in the liver whose major function is transport of vitamin A and thyroxine. Rare mutations in the transthyretin gene result in accumulation of large amyloid deposits of misfolded transthyretin molecules most prominently in peripheral nerves and the heart. Patients with hATTR typically present with polyneuropathy or autonomic dysfunction followed by cardiomyopathy which, if untreated, is fatal within 5 to 10 years.
|
Classification | Oligonucleotide |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 1867157-35-4 |
RxCUI | — |
ChEMBL ID | CHEMBL4594511 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB16699 |
UNII ID | GB4I2JI8UI (ChemIDplus, GSRS) |